{
    "clinical_study": {
        "@rank": "18309", 
        "arm_group": [
            {
                "arm_group_label": "PVI+renal denervation+OMT", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "PVI+GP ablation+OMT", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators  have conducted a prospective, double-blind, randomized study to assess\n      the comparative safety and efficacy of two different strategies, PVI plus Renal Denervation\n      (RD) versus PVI plus GP ablation, in patients with atrial fibrillation. Results were\n      assessed after follow-up of at least 1 year with the use of an implanted monitoring device\n      (IMD)."
        }, 
        "brief_title": "Ganglionated Plexi Ablation vs Renal Denervation in Patients Undergoing Pulmonary Vein Isolation", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Atrial Fibrillation", 
            "Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Atrial Fibrillation", 
                "Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Symptomatic drug-refractory AF (with history of failure of \u2265 2 class I or III\n             antiarrhythmic drugs) in patients referred for catheter ablation of AF\n\n          -  PAF with \u22651 monthly episodes or PersAF in patients who had already undergone \u22653\n             electrical cardioversions. PAF was defined as episodes lasting less than 7 days with\n             spontaneous termination. PersAF was defined as lasting more than 7 days before being\n             terminated pharmacologically or by electrical cardioversion.\n\n          -  History of significant hypertension (defined as SBP \u2265 160 mmHg and/or DBP \u2265 100\n             mmHg), receiving treatment with at least one antihypertensive medication\n\n          -  A glomerular filtration rate \u226545 mL/min/1\u22c573 m2, with modification of diet using a\n             renal disease formula\n\n        Exclusion Criteria:\n\n          -  Previous atrial fibrillation ablation\n\n          -  Type 1 of diabetes mellitus\n\n          -  Structural heart disease\n\n          -  Secondary cause of atrial hypertension\n\n          -  Severe renal artery stenosis or renal arteries abnormalities\n\n          -  Previous operations on renal arteries\n\n          -  Pregnancy\n\n          -  Previous heart, kidney, liver, or lung transplantation\n\n          -  Unwillingness of participant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01898910", 
            "org_study_id": "RDGP-031"
        }, 
        "intervention": [
            {
                "arm_group_label": "PVI+renal denervation+OMT", 
                "description": "After AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done.", 
                "intervention_name": "PVI+renal denervation", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "PVI+GP ablation+OMT", 
                "description": "To accomplish ganglionated plexi ablation, LA target sites were identified as the anatomic locations where vagal reflexes were evoked by transcatheter high-frequency stimulation (HFS). Rectangular electrical stimuli were delivered at a frequency of 20-50 Hz, output amplitude 15 V and pulse duration of 10 ms, for 5 sec (Stimulator B-53, Biotok Inc, Russia).", 
                "intervention_name": "PVI + GP ablation", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": [
                    "PVI+renal denervation+OMT", 
                    "PVI+GP ablation+OMT"
                ], 
                "description": "Antiarrhythmic and antihypertensive therapy will be administered according to the guidelines", 
                "intervention_name": "Optimal medial therapy (OMT)", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "July 12, 2013", 
        "link": {
            "description": "State Research Institute of Circulation Pathology Official Site", 
            "url": "http://meshalkin.ru"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Novosibirsk", 
                    "country": "Russian Federation", 
                    "zip": "630055"
                }, 
                "name": "State Research Institute of Circulation Pathology"
            }
        }, 
        "location_countries": {
            "country": "Russian Federation"
        }, 
        "number_of_arms": "2", 
        "official_title": "Ganglionated Plexi Ablation vs Renal Denervation in Patients Undergoing Pulmonary Vein Isolation. A Randomized Comparison", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Russia: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Freedom of AF or other atrial arrhythmias", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01898910"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Meshalkin Research Institute of Pathology of Circulation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Meshalkin Research Institute of Pathology of Circulation", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}